Stryker
Investments
3Portfolio Exits
3Partners & Customers
10Service Providers
2About Stryker
Stryker (NYSE: SYK) is a medical technology company that offers a diverse array of products and services in Orthopedics, Medical and Surgical, and Neurotechnology and Spine, which help improve patient and hospital outcomes.
Stryker Headquarter Location
2825 Airview Blvd
Kalamazoo, Michigan, 49002,
United States
269-385-2600
Expert Collections containing Stryker
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Stryker in 3 Expert Collections, including Fortune 500 Investor list.
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Medical Devices
4,103 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
Research containing Stryker
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Stryker in 2 CB Insights research briefs, most recently on May 6, 2021.

Latest Stryker News
May 13, 2022
May 13, 2022 “Focus on UI/UX (user interface and user experience) is paramount,” said Siddarth Satish, VP of Digital Innovation for the Surgical Technologies business at Stryker. [Photo courtesy of Stryker] Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The following has been lightly edited for space and clarity. Tracy Robertson [Photo courtesy of Stryker] Digital VP Tracy Robertson: We’re living in what’s called “The Age of the Customer.” Forrester Research termed that about 12-plus years ago. It started in retail and went through every industry. It’s now affecting [our] industry and transitioning into this industry in a major way. What’s happening is people are bringing their experiences — you’re doing it as well — from home to work: “If I can click this at home, why can’t I do that at work?” And you’re expecting that from your vendors at work, you just want brainless transactions. You want everything the same way at home as you do at work. And we have not been able to solve that or crack that at work, but that is the expectation. It has drastically changed. Experience is now a top purchasing criteria, almost at the same level as the product or service itself. So that is a huge challenge for companies. CX — customer experience — has now evolved into what we call the business of experience. We have to think about customers, our consumers, our patients, our ecosystem of customers, in how we design the product. Design, the product, the brand experience, our employees, their experience and the customer, it’s all integrated now. It’s a huge burden for us, but we’re competing against all of those things, it’s not just the product. I share all of that with you because in digital, you cannot separate experience from digital. For example, we can create all of these great products for our customers and create great data. And when we go to present it to our customers, if it’s hard to digest or it’s hard to interpret, it’s not a gift for them. It’s more work. There are a lot of adoption challenges in digital. So again, we can’t separate experience from digital, and that has to be part of the experience. That has to be a big part of how we start to design and think for our customers in the future. Otherwise we’ll have adoption challenges. Dave Lively is SVP of product management at Vocera (now part of Stryker). [Photo courtesy of Stryker] Dave Lively, SVP of product management, Vocera (now part of Stryker): We don’t write a single line of code until we’ve talked with doctors and nurses to get the experience right. And so we focus a lot on user-centered design. As soon as we’ve observed the problem or heard about a challenge from nurses and doctors, we’ll come back immediately with mockups: Does this address it? Does this address it? We’ll go through multiple iterations around the design of particular piece of software or a screen or a voice user interface to make sure that it’s solving the problem that the nurses and the doctors are having. Once we get that right — you can do a lot with just mockups and just design — then we’ll start writing the code. And then even after we write the code: Test it again, test it again, test it again. That human factors process has to start at the absolute beginning. Surgical Technologies VP of Digital Innovation Siddarth Satish: Focus on UI/UX (user interface and user experience) is paramount. With our product , we’re literally asking nurses in the middle of an OR to hold a bloody sponge up to an iPad and open it up. Think about that for a second. There’s a million things going on, it’s tough to do. We not only worked through that iterative cycle, we had to build and formalize human factors testing as part of our pathway through FDA. The agency has started to focus more and more and more on human factors. We’re seeing that a lot in these newer digital health technologies and during the pandemic through the EUA process with those at-home COVID test kits. It’s a really big deal. So we standardize and protocolize a lot of that. It’s built into every release cycle, even if we’re pushing a few lines of code, a small fix, there’s the question, “Does this qualify for a concerted test with, let’s say, 20 nurses to validate what we’ve done?” Robert Cohen [Photo courtesy of Stryker] Digital, Robotics, and Enabling Technologies President Robert Cohen: Human factors is part of all the Stryker efforts going forward. In fact, we’ve created panels for the human factors. In the old days, we’d get physicians coming to a cadaver lab when we were done. Now on our enabling tech — whether it’s software, things like that — workflow matters, efficiency matters, shortening the learning curve, what training cycle needs to be, what needs to be included in certification. So let’s just take a new robotics software for a new application. We get nurses involved. We’ve built OR simulation labs. We just built one in our new facility in Fort Lauderdale where we monitor behind glass. We have physicians, we have people in central supply that do cleaning of instruments and how to put things back. We’re labeling everything. So human factors and then usability is now included in all regulatory silos around the world. You may also like: Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re… Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly… Here’s where Harvard’s engineering dean sees medtech research going Tell Us What You Think!
Stryker Investments
3 Investments
Stryker has made 3 investments. Their latest investment was in Histogenics as part of their Series B on September 9, 2008.
Stryker Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/17/2008 | Series B | Histogenics | $9M | No | ||
1/10/2007 | Corporate Minority | |||||
8/17/2006 | Series A |
Date | 9/17/2008 | 1/10/2007 | 8/17/2006 |
---|---|---|---|
Round | Series B | Corporate Minority | Series A |
Company | Histogenics | ||
Amount | $9M | ||
New? | No | ||
Co-Investors | |||
Sources |
Stryker Portfolio Exits
3 Portfolio Exits
Stryker has 3 portfolio exits. Their latest portfolio exit was Stryker - T/Pump on February 16, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
2/16/2021 | Divestiture | 3 | |||
Date | 2/16/2021 | ||
---|---|---|---|
Exit | Divestiture | ||
Companies | |||
Valuation | |||
Acquirer | |||
Sources | 3 |
Stryker Acquisitions
43 Acquisitions
Stryker acquired 43 companies. Their latest acquisition was Vocera Communications on February 23, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
2/23/2022 | Series E+ | $50.4M | Acq - P2P | 6 | ||
9/7/2021 | Series C | $54.81M | Acquired | 2 | ||
1/5/2021 | Debt | $129.18M | Acquired | 11 | ||
11/11/2020 | Other Venture Capital | |||||
12/31/2019 | Series E+ |
Date | 2/23/2022 | 9/7/2021 | 1/5/2021 | 11/11/2020 | 12/31/2019 |
---|---|---|---|---|---|
Investment Stage | Series E+ | Series C | Debt | Other Venture Capital | Series E+ |
Companies | |||||
Valuation | |||||
Total Funding | $50.4M | $54.81M | $129.18M | ||
Note | Acq - P2P | Acquired | Acquired | ||
Sources | 6 | 2 | 11 |
Stryker Partners & Customers
10 Partners and customers
Stryker has 10 strategic partners and customers. Stryker recently partnered with Microbot Medical on December 12, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
12/27/2021 | Partner | Israel | Statements pertaining to the collaboration between the company and Stryker , the advancement of the LIBERTY Robotic System covered by the collaboration agreement and the potential benefits of such collaboration and statements pertaining to future financial and/or operating results , future growth in research , technology , clinical development , and potential opportunities for Microbot Medical Inc. and its subsidiaries , along with other statements about the future expectations , beliefs , goals , plans , or prospects expressed by management , constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws . | 3 | |
10/4/2021 | Partner | Australia | IMCRC industry partner Stryker to launch new Australian R&D facility - IMCRC CEO and Managing Director of IMCRC , David Chuter , congratulated Stryker on demonstrating strong industry leadership with this investment , and said the new facility represented the right framework for collaboration , industry growth and transformation in Australia . | 1 | |
9/3/2021 | Partner | United Kingdom | Stryker partners with Genesis to improve surgical safety , efficiency and outcomes . | 1 | |
4/29/2021 | Sponsored | ||||
4/22/2021 | Licensor |
Date | 12/27/2021 | 10/4/2021 | 9/3/2021 | 4/29/2021 | 4/22/2021 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Sponsored | Licensor |
Business Partner | |||||
Country | Israel | Australia | United Kingdom | ||
News Snippet | Statements pertaining to the collaboration between the company and Stryker , the advancement of the LIBERTY Robotic System covered by the collaboration agreement and the potential benefits of such collaboration and statements pertaining to future financial and/or operating results , future growth in research , technology , clinical development , and potential opportunities for Microbot Medical Inc. and its subsidiaries , along with other statements about the future expectations , beliefs , goals , plans , or prospects expressed by management , constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws . | IMCRC industry partner Stryker to launch new Australian R&D facility - IMCRC CEO and Managing Director of IMCRC , David Chuter , congratulated Stryker on demonstrating strong industry leadership with this investment , and said the new facility represented the right framework for collaboration , industry growth and transformation in Australia . | Stryker partners with Genesis to improve surgical safety , efficiency and outcomes . | ||
Sources | 3 | 1 | 1 |
Stryker Service Providers
2 Service Providers
Stryker has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Acq - P2P | Investment Bank | Sole Financial Advisor | |
Service Provider | ||
---|---|---|
Associated Rounds | Acq - P2P | |
Provider Type | Investment Bank | |
Service Type | Sole Financial Advisor |
Partnership data by VentureSource
Stryker Team
43 Team Members
Stryker has 43 team members, including current Chief Executive Officer, John Brown.
Name | Work History | Title | Status |
---|---|---|---|
Thomas Ressemann | Founder | Current | |
John Brown | Chief Executive Officer | Current | |
Andrew Fox-smith | President | Current | |
David Simpson | Chief Financial Officer | Current | |
Markus Wiegmann | Managing Director | Current |
Name | Thomas Ressemann | John Brown | Andrew Fox-smith | David Simpson | Markus Wiegmann |
---|---|---|---|---|---|
Work History | |||||
Title | Founder | Chief Executive Officer | President | Chief Financial Officer | Managing Director |
Status | Current | Current | Current | Current | Current |
You May Also Like

Arthrex is a global medical device company that specializes in new product development and medical education in orthopedics.
Inovedis is developing SINEFIX, a surgical technique and implant system for shoulder injuries that is based on a PEEK implant.
Activ is a developer of software to augment surgeons. It develops an AI/ML platform called ActivEdge, which is designed to provide real-time intelligence and visualization to surgeons. The company was founded in 2017 and is based in Boston, Massachusetts.

ConvaTec is a medical products and technologies company that focuses on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care and infusion devices. It is based in Reading, United Kingdom.

Imperative Care is reimagining how technology can solve stroke’s unmet needs, enabling healthcare providers with the ability to raise the standard of care for patients.
Teleflex Medical, fka Hudson Respiratory Care, manufactures and markets surgical instruments and devices in the United States and internationally. It offers surgical instruments and devices, cardiac devices, and other specialty products.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.